(Albany, USA) DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Narcolepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Narcolepsy Market Forecast

 

Some of the key facts of the Narcolepsy Market Report: 

• The Narcolepsy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the United States, narcolepsy is thought to afflict 1 in every 2,000 persons, according to the Narcolepsy Network Organisation. In contrast to paediatrics, adults are more often than children to suffer from narcolepsy, a sleep disease that is underdiagnosed
• Slowik et al. (2022) estimate that the prevalence of narcolepsy type 1 is 14 per 100,000 people and type 2 is 65.4 per 100,000. According to research from 2008 to 2010, it is most common in those who are in their late teens or early twenties, with a 50% larger female preponderance
• In a Japanese study that employed a database of health insurance claims, Imanishi et al. (2022) reported that the overall yearly prevalence increased from 5.7 to 18.5/100,000 people in 2010 and 2019, respectively
• The demand for narcolepsy patients’ treatment alternatives is extremely high. A number of the products in the pipeline, including LUMRYZ (FT-218) (Avadel), Samelisant (SUVNG3031) (Suven Life Sciences), and Quilience (NLS Pharmaceutics), are anticipated to go on sale during the projected period [2023-2032]
• Key Narcolepsy Companies: Avadel Pharmaceuticals, Suven Life Sciences, NLS Pharmaceuticals, Taisho Pharmaceutical, Jazz Pharmaceuticals, Takeda, Alza Corporation, DE, Suven Life Sciences Ltd., Cephalon, Pfizer, Axsome Therapeutics, Inc., Orphan Medical, NLS Pharmaceutics, and others
• Key Narcolepsy Therapies: LUMRYZ (FT218), Samelisant (SUVN-G3031), QUILIENCE (mazindol), TS-091, JZP-258, TAK-861, JNJ-17216498, SUVN-G3031, Xyrem, Modafinil, PF-03654746, AXS-12 (Reboxetine), sodium oxybate, mazindol extended release, and others
• The Narcolepsy epidemiology based on gender analyzed that females are more affected with narcolepsy (type1) than males
• The Narcolepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Narcolepsy pipeline products will significantly revolutionize the Narcolepsy market dynamics.

 

Narcolepsy Overview

A long-term neurological/brain condition called narcolepsy causes irregular sleep and awake patterns.An excessive amount of daytime sleepiness and abrupt, uncontrollable episodes of falling asleep at any time of the day are symptoms of narcolepsy.

 

Get a Free sample for the Narcolepsy Market Report: https://www.delveinsight.com/report-store/narcolepsy-market

 

Narcolepsy Epidemiology

The Narcolepsy epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Narcolepsy Epidemiology Segmentation:

The Narcolepsy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Narcolepsy
• Prevalent Cases of Narcolepsy by severity
• Gender-specific Prevalence of Narcolepsy
• Diagnosed Cases of Episodic and Chronic Narcolepsy

 

Download the report to understand which factors are driving Narcolepsy epidemiology trends @ Narcolepsy Epidemiology Forecast

 

Narcolepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched during the study period. The analysis covers Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Narcolepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Narcolepsy Therapies and Key Companies

• LUMRYZ (FT218): Avadel Pharmaceuticals
• Samelisant (SUVN-G3031): Suven Life Sciences
• QUILIENCE (mazindol): NLS Pharmaceuticals
• TS-091: Taisho Pharmaceutical
• JZP-258: Jazz Pharmaceuticals
• TAK-861: Takeda
• JNJ-17216498: Alza Corporation, DE
• SUVN-G3031: Suven Life Sciences Ltd.
• Xyrem: Jazz Pharmaceuticals
• Modafinil: Cephalon
• PF-03654746: Pfizer
• AXS-12 (Reboxetine): Axsome Therapeutics, Inc.
• sodium oxybate: Orphan Medical
• mazindol extended release: NLS Pharmaceutics

 

Discover more about therapies set to grab major Narcolepsy market share @ Narcolepsy Treatment Market

 

Narcolepsy Market Strengths

• Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in narcolepsy
• The increasing prevalence of narcolepsy, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact themarket in the near future

 

Narcolepsy Market Opportunities

• Identify potential therapeutic targets and strategies for improving quality of life, and restore functional levels of those who suffer from Narcolepsy
• To understand the transition from acute to narcolepsy, how peripheral and central sensitization is manifested, and how they can be assessed

 

Scope of the Narcolepsy Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Narcolepsy Companies: Avadel Pharmaceuticals, Suven Life Sciences, NLS Pharmaceuticals, Taisho Pharmaceutical, Jazz Pharmaceuticals, Takeda, Alza Corporation, DE, Suven Life Sciences Ltd., Jazz Pharmaceuticals, Cephalon, Pfizer, Axsome Therapeutics, Inc., Orphan Medical, NLS Pharmaceutics, and others
• Key Narcolepsy Therapies: LUMRYZ (FT218), Samelisant (SUVN-G3031), QUILIENCE (mazindol), TS-091, JZP-258, TAK-861, JNJ-17216498, SUVN-G3031, Xyrem, Modafinil, PF-03654746, AXS-12 (Reboxetine), sodium oxybate, mazindol extended release, and others
• Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies
• Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Narcolepsy Unmet Needs, KOL’s views, Analyst’s views, Narcolepsy Market Access and Reimbursement 

 

To know more about Narcolepsy companies working in the treatment market, visit @ Narcolepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Narcolepsy Market Report Introduction

2. Executive Summary for Narcolepsy

3. SWOT analysis of Narcolepsy

4. Narcolepsy Patient Share (%) Overview at a Glance

5. Narcolepsy Market Overview at a Glance

6. Narcolepsy Disease Background and Overview

7. Narcolepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Narcolepsy 

9. Narcolepsy Current Treatment and Medical Practices

10. Narcolepsy Unmet Needs

11. Narcolepsy Emerging Therapies

12. Narcolepsy Market Outlook

13. Country-Wise Narcolepsy Market Analysis (2019–2032)

14. Narcolepsy Market Access and Reimbursement of Therapies

15. Narcolepsy Market Drivers

16. Narcolepsy Market Barriers

17.  Narcolepsy Appendix

18. Narcolepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services